{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cyclophosphamide&page=42",
    "query": {
      "intervention": "cyclophosphamide",
      "page": 42
    },
    "page_size": 10
  },
  "pagination": {
    "page": 42,
    "page_size": 10,
    "total_count": 2804,
    "total_pages": 281,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cyclophosphamide&page=43&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cyclophosphamide&page=41&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-01T04:21:45.633Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01464359",
      "title": "T-Cell Depleted Double UCB for Refractory AML",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia",
        "Refractory Acute Myelogenous Leukemia"
      ],
      "interventions": [
        {
          "name": "Allopurinol",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Total body irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Levetiracetam",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Umbilical Cord Blood Transplantation",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Interleukin-2",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "BIOLOGICAL"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "2 Years to 45 Years"
      },
      "enrollment_count": 3,
      "start_date": "2011-10",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2017-12-28",
      "last_synced_at": "2026-11-01T04:21:45.633Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01464359"
    },
    {
      "nct_id": "NCT06451159",
      "title": "A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Progressive Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "KYV-101 (Biological) - 0.33 ×10^8 cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "KYV-101 (Biological) - 1 ×10^8 cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Chemotherapy: cyclophosphamide (CYC)",
          "type": "DRUG"
        },
        {
          "name": "Chemotherapy: fludarabine (FLU)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Bruce Cree",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "25 Years to 70 Years"
      },
      "enrollment_count": 10,
      "start_date": "2024-06-20",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2026-08-10",
      "last_synced_at": "2026-11-01T04:21:45.633Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06451159"
    },
    {
      "nct_id": "NCT04282174",
      "title": "CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hematologic Diseases",
        "Hematologic Malignancy",
        "Acute Lymphoblastic Leukemia",
        "Acute Myeloid Leukemia",
        "Chronic Myelogenous Leukemia",
        "Chronic Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "CliniMACS",
          "type": "DEVICE"
        },
        {
          "name": "Bone Marrow Transplant",
          "type": "PROCEDURE"
        },
        {
          "name": "Hyperfractionated Total Body Irradiation",
          "type": "DRUG"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Baptist Health South Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "Up to 74 Years"
      },
      "enrollment_count": 0,
      "start_date": "2022-09",
      "completion_date": "2030-03-01",
      "has_results": false,
      "last_update_posted_date": "2022-09-27",
      "last_synced_at": "2026-11-01T04:21:45.633Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04282174"
    },
    {
      "nct_id": "NCT01959490",
      "title": "Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage II Breast Cancer",
        "Stage IIIA Breast Cancer",
        "Stage IIIB Breast Cancer",
        "Stage IIIC Breast Cancer"
      ],
      "interventions": [
        {
          "name": "trastuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pertuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 16,
      "start_date": "2013-09-24",
      "completion_date": "2017-03-29",
      "has_results": true,
      "last_update_posted_date": "2019-03-05",
      "last_synced_at": "2026-11-01T04:21:45.633Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01959490"
    },
    {
      "nct_id": "NCT02073097",
      "title": "Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Contiguous Stage II Adult Diffuse Large Cell Lymphoma",
        "Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma",
        "Stage I Adult Diffuse Large Cell Lymphoma",
        "Stage III Adult Diffuse Large Cell Lymphoma",
        "Stage IV Adult Diffuse Large Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Carfilzomib",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Vincristine sulfate",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Pegfilgrastim",
          "type": "DRUG"
        },
        {
          "name": "Acyclovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2015-01-28",
      "completion_date": "2023-06-29",
      "has_results": true,
      "last_update_posted_date": "2024-05-29",
      "last_synced_at": "2026-11-01T04:21:45.633Z",
      "location_count": 3,
      "location_summary": "Buffalo, New York • Cleveland, Ohio",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02073097"
    },
    {
      "nct_id": "NCT04002115",
      "title": "Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Clofarabine",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Total Body Irradiation (TBI)",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Granulocyte Colony-Stimulating Factor",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Cellcept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Milton S. Hershey Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 2,
      "start_date": "2020-06-03",
      "completion_date": "2022-11-07",
      "has_results": true,
      "last_update_posted_date": "2023-09-14",
      "last_synced_at": "2026-11-01T04:21:45.633Z",
      "location_count": 1,
      "location_summary": "Hershey, Pennsylvania",
      "locations": [
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04002115"
    },
    {
      "nct_id": "NCT06420089",
      "title": "CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "T Cell Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Senza5 CART5",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vittoria Biotherapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2024-10-04",
      "completion_date": "2029-08-30",
      "has_results": false,
      "last_update_posted_date": "2025-11-10",
      "last_synced_at": "2026-11-01T04:21:45.633Z",
      "location_count": 2,
      "location_summary": "New York, New York • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06420089"
    },
    {
      "nct_id": "NCT00586560",
      "title": "Karenitecin in Pediatric Patients With Refractory or Recurrent Solid Tumors N10010)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Kareniticin and cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "12 Months to 21 Years"
      },
      "enrollment_count": 15,
      "start_date": "2007-02",
      "completion_date": "2011-01",
      "has_results": false,
      "last_update_posted_date": "2012-05-15",
      "last_synced_at": "2026-11-01T04:21:45.633Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00586560"
    },
    {
      "nct_id": "NCT00211185",
      "title": "A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma, T-Cell, Peripheral"
      ],
      "interventions": [
        {
          "name": "Denileukin diftitox",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Pegfilgrastim",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2004-03-14",
      "completion_date": "2009-12-23",
      "has_results": true,
      "last_update_posted_date": "2020-03-18",
      "last_synced_at": "2026-11-01T04:21:45.633Z",
      "location_count": 49,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Stanford, California + 42 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00211185"
    },
    {
      "nct_id": "NCT00326417",
      "title": "Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Anemia, Aplastic"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide 150mg",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide 100mg",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide 50mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "Up to 65 Years"
      },
      "enrollment_count": 97,
      "start_date": "2006-01",
      "completion_date": "2016-01",
      "has_results": true,
      "last_update_posted_date": "2021-10-28",
      "last_synced_at": "2026-11-01T04:21:45.633Z",
      "location_count": 22,
      "location_summary": "Phoenix, Arizona • Duarte, California • Los Angeles, California + 17 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00326417"
    }
  ]
}